conference - biotechnology innovation organization new approaches include allogenic car-t products,...

bio.org/CEO • #BIOCEO18

CE NVESTORCONFERENCE

February 12-13, 2018New York Marriott MarquisNew York, New York

http://bio.org/CEO

2 FEBRUARY 12-13, 2018 | NEW YORK, NEW YORK

WHY ATTEND? 8 EXPERIENCE the largest, unbiased forum where institutional

investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry.

8 EVALUATE fresh investment opportunities including compatible, complementary and competitive companies.

8 LEARN about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables.

8 ATTEND fireside chats with leading executives who will share their recent company successes and general industry perspectives.

8 GAIN ACCESS to BIO’s One-on-One Partnering system for scouting potential investments and deal partners, optimizing your time at the event.

8 HEAR presentations from more than 175 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences.

8 GET THE PULSE of the current and proposed investment trends in biotechnology.

8 NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions.

CEO INVESTORCONFERENCE

Now in its 20th year, the BIO CEO &

Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

8 2

3BIO.ORG/CEO • #BIOCEO18CEO INVESTORCONFERENCEFebruary 13 – 14, 2017The Waldorf Astoria, New York, New York

Fireside Chats feature candid discussions

between biopharma executives, Wall Street analysts, and other high-level industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2018.

2018 FIRESIDE CHAT SPEAKERS

Deborah Dunsire, MDPresident and Chief Executive OfficerXTuit Pharmaceuticals

Jeffrey D. MarrazzoCo-Founder and Chief Executive OfficerSpark Therapeutics

Vicki Sato, PhDChairmanDenali TherapeuticsChairmanVir Biotechnology

Lan Huang, PhDCo-Founder, Chairman and Chief Executive OfficerBeyondSpring Pharmaceuticals

Vivek RamaswamyFounder and Chief Executive OfficerRoivant Sciences

Rachel Sherman, MD, MPHPrincipal Deputy CommissionerU.S. Food and Drug Administration (FDA)


MONDAY � FEBRUARY 12

9:00 am – 4:15 pm Company Presentations9:00 am – 10:15 am Therapeutic Panel

Immuno-Oncology Milestones to Come: Pipelines Beyond CAR-T 1.0

10:30 am – 11:25 am Fireside ChatJeffrey D. Marrazzo, Co-Founder and Chief Executive Officer, Spark Therapeutics

12:00 pm – 12:55 pm Business SessionThe Art of the Exit: Planning for Your Company’s Acquisition

1:00 pm – 1:55 pm Business SessionUpdating Your China Growth Strategy: Opportunities in Investor and Regulatory Dynamism

2:00 pm – 2:55 pm Fireside ChatLan Huang, PhD, Co-Founder, Chairman and Chief Executive Officer, BeyondSpring Pharmaceuticals

3:00 pm – 3:55 pm Business SessionFunding Cures: Prioritizing Policy Barriers to Amortization of Therapeutic Spending

4:00 pm – 4:55 pm Therapeutic PanelAdvances in Dermatology: Recent Approvals and Later-Stage Trials

5:00 pm – 5:55 pm Business SessionMarket Outlook—How Durable is the IPO Resurgence and M&A Slowdown?

6:00 pm – 7:00 pm Welcome Reception

TUESDAY � FEBRUARY 13

9:00 am – 3:45 pm Company Presentations9:00 am – 9:55 am Therapeutic Panel

Neuroscience of Addiction: Levers to Attack the Opioid Abuse Crisis

10:00 am – 10:55 am Fireside ChatDeborah Dunsire, MD, President and Chief Executive Officer, XTuit Pharmaceuticals

11:00 am – 11:55 am Business SessionPolicy Outlook—Implications of the Tax Code Changes of the Trump Administration

12:00 pm – 12:55 pm Fireside ChatRachel Sherman, MD, MPH, Principal Deputy Commissioner, U.S. Food and Drug Administration (FDA)

1:00 pm – 1:55 pm Business SessionInstilling Innovation Ambitions in your Leadership Culture

2:00 pm – 2:55 pm Fireside ChatVivek Ramaswamy, Founder and Chief Executive Officer, Roivant Sciences

3:00 pm – 3:55 pm Therapeutic PanelChronic Disease Innovation: PCSK9 Treatments’ Early Lessons for Other Therapies

4:00 pm – 4:55 pm Fireside ChatVicki Sato, PhD, Chairman, Denali Therapeutics; Chairman, Vir Biotechnology

5:00 pm – 6:00 pm Closing Reception

2018 AGENDA


MONDAY � FEBRUARY 12

IMMUNO-ONCOLOGY MILESTONES TO COME: PIPELINES BEYOND CAR-T 1.09:00 am – 10:15 am As the recently approved, initial CAR-T therapies have shown they can produce dramatic

improvements for some closely defined patient populations, the next phase of attention shifts to stretching those immuno-oncology (I-O) findings into additional targets, platforms, and indications. These new approaches include allogenic CAR-T products, T-cell regulators, oncolytic viruses, natural killer (NK) cells, and other I-O technologies. This session will discuss the dynamic opportunities in this space to fight cancer even more effectively.

MODERATOR: Asthika Goonewardene, Senior Biotech Analyst, Bloomberg IntelligencePANELISTS: Sadik Kassim, PhD, Vice President, Head of Process and Analytical Development,

Mustang Bio Didier Landais, Global Head of Licensing, Servier Charles Link, MD, Co-Founder, Chairman, CEO, Chief Scientific Officer,

NewLink Genetics Kimberly Noonan, PhD, Founder and Chief Scientific Officer, WindMIL* Kenneth Pienta, MD, Acting Chief Medical Officer, Cue Biopharma* Tito A. Serafini, PhD, President, Chief Executive Officer, and Co-Founder,

Atreca, Inc.

THE ART OF THE EXIT: PLANNING FOR YOUR COMPANY’S ACQUISITION12:00 pm – 12:55 pm There are times when a company for reasons such as clinical trial expense, achieving scale in

a global sales force, or needing manufacturing capacity, recognizes that shareholder returns are best served by being acquired by a strategic buyer. Leadership teams that manage their process well can maximize the eventual benefits for their shareholders, employees, and patients of this transformation through careful partner identification, negotiations management, and integration planning. This session will feature experienced perspectives on the do’s and don’ts for CEOs considering options for proactive selling of their companies, rather than just reacting to external purchase offers.

MODERATOR: Kimberly C. Petillo-Décossard, Partner, Cahill Gordon & Reindel LLPPANELISTS: Barbara Dalton, PhD, Vice President, Venture Capital, Pfizer Inc. Linda S. Grais, MD, President and Chief Executive Officer, Ocera Therapeutics, Inc.* Derek Hicks, Senior Director, Worldwide Business Development, Pfizer Inc. Annalisa Jenkins, MBBS, MRCP, former Chief Executive Officer, Dimension Therapeutics* Kazumi Shiosaki, PhD, Managing Director, MPM Capital; former Chief Executive

Officer, Mitobridge* Neil Warma, Director, Orpheris; President & Chief Executive Officer,

Opexa Therapeutics, Inc.

*invited


UPDATING YOUR CHINA GROWTH STRATEGY: OPPORTUNITIES IN INVESTOR AND REGULATORY DYNAMISM1:00 pm – 1:55 pm The policy shifts announced by the CFDA and Chinese investment authorities within the

past two years have unlocked significant new opportunities for biopharma companies to access the patient population in China and obtain capital from new sources. Already the world’s second largest market for biopharmaceuticals, the increasing pace of drug reviews and harmonization of clinical trials expectations means companies should revisit their market launch prioritizations. This session will share advice from successful leaders in this market for partnering with Chinese biopharmas and investors.

MODERATOR: Joseph Damond, Executive Vice President, International Affairs, Biotechnology Innovation Organization (BIO)PANELISTS: Michael Keyoung, MD, PhD, Managing Director and Head of North America,

C-Bridge Capital Yuwen Liu, Founding Partner, BOHE Angel Fund; former Chairwoman & CEO,

Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY)* Kimberly Nearing, Managing Director and Head of Life Sciences,

Cedrus Investments Hummer Mars, Executive Director, China Group, Global Investment

Banking Division, NYIC Amit D. Munshi, Director, President, and Chief Executive Officer,

Arena Pharmaceuticals* Dan Zhang, MD, Chairman, Fountain Medical Development Ltd. (FMD)

FUNDING CURES: PRIORITIZING POLICY BARRIERS TO AMORTIZATION OF THERAPEUTIC SPENDING3:00 pm – 3:55 pm The tradition of health systems paying for biopharma treatments by the dose gets strained

when confronted by the latest therapeutic technologies that may offer multi-year benefits or lifetime relief from disease per a single administration of a highly customized therapy. Finding analogous methods of matching payment schedules to long-duration benefits, while covering up-front costs, shows how unprepared organizations are for the era of delivering access to gene therapies and other potential cures. This session will consider market-based options and identify relevant policy barriers to experimenting with amortization models and other techniques for funding non-traditional treatments that could greatly improve or extend patients’ lives.

*invited

MONDAY � FEBRUARY 12, 201810:30 am – 11:25 amJeffrey D. MarrazzoCo-Founder and Chief Executive Officer, Spark Therapeutics MODERATOR: Erin McCallister, Senior Editor, BioCentury

2:00 pm – 2:55 pmLan Huang, PhDCo-Founder, Chairman and Chief Executive Officer, BeyondSpring PharmaceuticalsMODERATOR: Joseph Pantginis, PhD, Managing Director, Senior Healthcare Analyst, H. C. Wainwright and Co., LLC

FIRESIDE CHATS


PANELISTS: Ted Haack, Owner, Managing Partner, Haack & Associates* Jami Rubin, Managing Director, Goldman Sachs* Michael B. Weiss, Partner, Cahill Gordon & Reindel LLP

ADVANCES IN DERMATOLOGY: RECENT APPROVALS AND LATER-STAGE TRIALS4:00 pm – 4:55 pm 2017 produced seven FDA approvals for new dermatology medicines, the most since 2014.

Additionally, several treatments in late-stage clinical development suggest opportunities for new help for patients suffering from some chronic and acute skin ailments. This session will examine some of the exciting clinical results illuminating biological understanding of dermatological diseases and the emerging opportunities for investors in this space.

MODERATOR: Umer Raffat, Senior Managing Director, Evercore ISI*PANELISTS: Alise Reicin, MD, Head of Global Clinical Development, Merck KGaA* Baldo Sforzolini, MD, PhD, MBA, Senior Vice President, Clinical Development,

Allergan* Michael Sierra, PhD, Vice President, LEO Science & Tech Hub Neal Walker, MD, President and Chief Executive Officer, Aclaris* Tom Wiggans, Chairman and Chief Executive Officer, Dermira* Elias Zerhouni, Global Head of R&D, Sanofi*

MARKET OUTLOOK—HOW DURABLE IS THE IPO RESURGENCE AND M&A SLOWDOWN?5:00 pm – 5:55 pm With more than 30 biotech IPOs in 2017 but M&A deal activity running at lower than average

levels, the tension for CEOs is delivering a confident story of how to achieve profitable growth for investors while drug launches receive more scrutiny than ever. As large biopharmas prune their portfolios and consider their repatriation options, the expectations run high for an uptick in M&A in 2018. This session will include experienced deal makers and investors sharing their perspectives on where they see the promise of intensifying activity within the industry this year.

MODERATOR: Stephen B. Thau, Partner, Morrison & Foerster LLPPANELISTS: James Cappuccio, Managing Director, H.C. Wainwright and Co., LLC Chris Garabedian, Chairman and CEO, Xontogeny Stefan D. Loren, PhD, Managing Director, Healthcare Investment Banking,

Oppenheimer & Co. Michael Meyers, Interim Chief Executive Officer, Tivorsan Pharmaceuticals, Inc. Matthew Roden, PhD, Head of Strategic Corporate Development and Global BD

Assessment, Bristol-Myers Squibb Sapna Srivastava, PhD, Chief Financial Officer and Chief Strategy Officer,

Abide Therapeutics

*invited


TUESDAY � FEBRUARY 13

NEUROSCIENCE OF ADDICTION: LEVERS TO ATTACK THE OPIOID ABUSE CRISIS9:00 am – 9:55 am With official recognition of the magnitude of the opioid abuse crisis, government institutions

and investors are showing increased willingness to support novel approaches to attacking this health challenge. This session will explore the most promising avenues in the neuroscience of addiction and alternatives to opioid-based pain management, as well as identify the most pressing bottlenecks in our understanding of the brain’s addiction to painkillers.

PANELISTS: Roger Crystal, MD, Chief Executive Officer, Opiant Robert Hadie, President and Chief Executive Officer, Egalet Corporation Lucy Lu, MD, President and CEO, Avenue Therapeutics Corey McCann, MD, PhD, Founder and Chief Executive Officer,

Pear Therapeutics Peter Strumpf, President and Chief Executive Officer, Amygdala Neurosciences Inc.*

POLICY OUTLOOK—IMPLICATIONS OF THE TAX CODE CHANGES OF THE TRUMP ADMINISTRATION11:00 am – 11:55 am As the U.S. tax code experiences its greatest changes in decades, the financial assumptions

underlying investors’ valuations will shift significantly, creating some new advantages and disadvantages within the biopharma community. This session will explain in depth the implications for pre-market and for commercial biopharma companies of changes to R&D credits, orphan drug credits, repatriation conditions, and other key dimensions of the tax rules for 2018, plus where policy adjustments might be worth recommending.

MODERATOR: Andrew J. Silverman, Government Analyst–Tax, Bloomberg IntelligencePANELISTS: Mitchell Cohen, Global Tax Leader Life Sciences, EY* Michael J. Graetz, Columbia Alumni Professor of Tax Law, Columbia University* Robert Masella, Partner, Shearman & Sterling* Jacqueline Perrotti, Executive Director, Tax, Allergan*

INSTILLING INNOVATION AMBITIONS IN YOUR LEADERSHIP CULTURE1:00 pm – 1:55 pm As the scientific challenges of developing new and superior treatments increase in difficulty,

corporate management’s ability to maximize the capacity of their teams to innovate becomes ever more urgent. Recent research in cognitive science and comparative stock investment results suggest clear performance advantages that more highly diversified teams and boards can deliver. Traditional recruitment processes for corporate executive teams often fail to reflect the employee bases they lead or patient populations they serve. This session will focus on practical approaches and successful examples to diversify leadership recruitment efforts, create inclusive cultures for development/retention, and better align organizations with the full measure of talented people available.

MODERATOR: James Sapirstein, RPh, Chief Executive Officer, ContraVirPANELISTS: Karen Anderson, Senior Vice President, Chief Human Resources Officer,

Alnylam Pharmaceuticals Wanda Bryant Hope, Chief Diversity & Inclusion Officer, Johnson & Johnson Sabrina Martucci Johnson, Chief Executive Officer, Daré Bioscience Inc.* Karen Ling, Executive Vice President, Chief Human Resources Officer, Allergan*

*invited


TUESDAY � FEBRUARY 13, 201810:00 am – 10:55 amDeborah Dunsire, MDPresident and Chief Executive Officer, XTuit PharmaceuticalsMODERATOR: Yasmeen Rahimi, PhD, Director, Research Analyst, ROTH Capital Partners

12:00 pm – 12:55 pmRachael Sherman, MD, MPHPrincipal Deputy Commissioner, U.S. Food and Drug Administration (FDA)MODERATOR: James C. Greenwood, President and Chief Executive Officer,

Biotechnology Innovation Organization (BIO)

2:00 pm – 2:55 pmVivek RamaswamyFounder and Chief Executive Officer, Roivant Sciences

4:00 pm – 4:55 pmVicki Sato, PhDChairman, Denali Therapeutics; Chairman, Vir BiotechnologyMODERATOR: Kate Merton, PhD, Head, JLABS @ NYC, Johnson & Johnson Innovation

FIRESIDE CHATS

CHRONIC DISEASE INNOVATION: PCSK9 TREATMENTS’ EARLY LESSONS FOR OTHER THERAPIES3:00 pm – 3:55 pm While a majority of venture funding goes into development of oncology and rare disease

treatments, the broader population with chronic diseases can also look forward to innovations from established biopharmas as well as smaller companies with promising new approaches to compete with existing care options. The slower-than-projected growth of the PCSK9 segment, despite clear clinical advantages, suggests that commercialization within the chronic disease space presents particular recent challenges that companies should be prepared to overcome once their medicines receive approvals and roll-out begins. This session will highlight some exciting late-stage pipelines and review the structural challenges of convincing providers, payers, and patients of the value of a new medicine for treating a chronic disease which has existing therapeutic alternatives.

MODERATOR: Susan Peschin, MHS, President and Chief Executive Officer, Alliance for Aging Research

PANELISTS: Paul A. Friedman, MD, Chairman and Chief Executive Officer, Madrigal Pharmaceuticals*

Carol Gallagher, PharmD, Partner, New Enterprise Associates* Nouhad Husseini, Vice President, Head of Business Development,

Regeneron Pharmaceuticals, Inc.* Jim Tobin, PhD, Vice President, Scientific Innovation, Cardiovascular & Metabolic,

Johnson & Johnson Innovation

Visit bio.org/ceo for latest listings. Sessions, speakers, and presentations are subject to change.

*invited


2018 PRESENTING COMPANIESThe 2018 BIO CEO & Investor Conference will better accommodate the growing diversity of

investors and companies. While the majority of presenting companies at this event are publicly traded, with about half trading with market capitalizations above $100M, this meeting will once again feature a unique track of more than 30 high-caliber and established private company presentations. This year, BIO has introduced a new track of “Emerging Innovators” comprised of pre-Series A, but post-startup companies. See bio.org/ceo for a downloadable spreadsheet of presenting companies’ info.Cardiology Aralez Pharmaceuticals (NASDAQ:ARLZ) Berlin Cures Cardiol Therapeutics Inc Espero BioPharma, Inc. Resverlogix Corp. (TSX:RVX)

CNS/NeurologicalAbide TherapeuticsAmygdala Neurosciences, Inc.Anavex Life Sciences Corp. (NASDAQ:AVXL)Aralez Pharmaceuticals (NASDAQ:ARLZ) Assuage Pharmaceuticals, Inc. Aucta Pharmaceuticals Inc. Axsome Therapeutics (NASDAQ:AXSM)Bioasis Technologies Inc. (TSX.V / OTCQB:BTI / BIOAF) Berlin Cures Cardiol Therapeutics Inc Corium International, Inc. (NASDAQ:CORI)Espero BioPharma, Inc. Flex Pharma (NASDAQ:FLKS)Genervon Biopharmaceuticals, LLCNeuraltus Pharmaceuticals, Inc. NeuroActiva, Inc. NeuroRx, Inc.Neurotrope (NASDAQ:NTRP) Newron Pharmaceuticals SpA (SIX:NWRN)Oryzon Genomics SA (BOLSA:ORY) PAION AG (Xetra, Frankfurt:PA8)Probiodrug AG (Euronext Amsterdam:PBD)Resverlogix Corp. (TSX:RVX) Serina Therapeutics, Inc. TAHO Pharmaceuticals Ltd. (TPEX:tw.6467)Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Contract Research OrganizationBrillance

DermatologyExicure Inc. (OTCQB:XCUR)Fibrocell Science, Inc. (NASDAQ:FCSC)Moberg Pharma AB (Nasdaq Stockholm:MOB.ST)

DiagnosticsBiocept, Inc. (NASDAQ:BIOC)Chembio Diagnostics, Inc. (NASDAQ:CEMI)Curetis N.V. (Euronext Amsterdam & Euronext Brus-

sels:CURE) Interpace Diagnostics (NASDAQ:IDXG)Intuitive Biosciences, Inc. Invitae Corporation (NYSE:NVTA) Mikro Biyosistemler Elektronik Sanayi ve Ticaret AŞ Navidea Biopharmaceuticals (NYSE:NAVB) OncoCyte Corporation (NYSE American:OCX)Valdia Health

Digital HealthPear Therapeutics, Inc.TraceLink

Food & AgricultureRecombinetics Inc.

GastrointestinalAzurRx BioPharma, Inc. (NASDAQ:AZRX)Conatus Pharmaceuticals Inc. (NASDAQ GM:CNAT)Enterome SALandos BiopharmaLeading BioSciencesOrphoMed, Inc.RedHill Biopharma Ltd. (NASDAQ/TASE:RDHL)

Gene/Cell TherapyBioLife Solutions, Inc. (NASDAQ:BLFS)Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)Caladrius Biosciences, Inc. (NASDAQ:CLBS)

Cesca Therapeutics, Inc. (NASDAQ:KOOL)Editas Medicine, Inc. (NASDAQ:EDIT)Humanigen, Inc. (OTCQB: HGEN) MangoGen Pharma Orig3n, Inc. Sigilon Therapeutics IncSQZ BiotechnologiesVericel Corporation (NASDAQ:VCEL)

ImmunologyCytoDyn, Inc. (OTC Markets:CYDY)Gradalis, Inc. Heat Biologics (NASDAQ:HTBX)Hemispherx Biopharma, Inc. (NYSE:HEB)Immunovaccine Inc (TSX, OTCQX:IMV, IMMVF)ImmusanT, Inc.NewLink Genetics (NASDAQ:NLNK)

Immuno-oncologyImmunomic Therapeutics, Inc.

Infectious DiseasesAridis Pharmaceuticals, Inc.Armis Biopharma, Inc. ContraVir Pharmaceuticals (NASDAQ:CTRV)Lakewood-Amedex, Inc.Synthetic Biologics, Inc. (NYSE American:SYN)TAXIS Pharmaceuticals Inc.Vical Incorporated (NASDAQ:VICL)

InflammationImmune Pharmaceuticals Inc. (NASDAQ:IMNP) Morphic Therapeutic Inc.

Medical DevicesBellerophon Therapeutics (NASDAQ:BLPH)CytoSorbents Corporation (NASDAQ:CTSO)Femeda Ltd gel-e, Inc. Microdermics Inc.Sanuwave Health, Inc. (OTCQB:SNWV)

Metacbolic DiseasesAdocia (Euronext Paris: ADOC)Gila Therapeutics, Inc. Orexigen Therapeutics, Inc. (NASDAQ:OREX)Viking Therapeutics, Inc. (NASDAQ:VKTX)

Multiline Global BiopharmaDyadic International, Inc. (OTCQX:DYAI)

Multiple TherapeuticsAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Can-Fite BioPharma Ltd. (NYSE:CANF)Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)Galectin Therapeutics, Inc. (NASDAQ:GALT)Palatin Technologies, Inc. (NYSE:MKT:PTN)

Non-Profit/Patient Advocacy GroupAssociation for Women in Science (AWIS)

OncologyActinium Pharmaceuticals, Inc. (NYSE American:ATNM)Apexian PharmaceuticalsAravive BiologicsBioLineRx Ltd. (NASDAQ:BLRX)Bio-Path Holdings, Inc. (NASDAQ:BPTH)Cellectar Biosciences (NASDAQ:CLRB)CEL-SCI Corporation (NYSE American:CVM)Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)Cue Biopharma (NASDAQ:CUE) Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)CytRx Corporation (NASDAQ:CYTR)Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)Erytech Pharma (NASDAQ:ERYP) Forty Seven Inc.

Gritstone Oncology, Inc.H3 Biomedicine Humanetics Corporation Immunicum AB (Nasdaq Stockholm:IMMU.ST)Infinity Pharmaceuticals, Inc. (Nasdaq:INFI)Inovio Pharmaceuticals (NASDAQ:INO)Intensity Therapeutics, Inc. InteRNA Technologies B.V. Lantern Pharma IncLeap Therapeutics Inc. (NASDAQ:LPTX) Lexi Pharma Inc.MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX)MaxCyte, Inc. (AIM, LSE:MXCT; MXCR)NanOlogy LLC Opsona Therapeutics LimitedProgenics Pharmaceuticals, Inc. (NASDAQ:PGNX)Race Oncology Ltd (ASX:RAC)Rain Therapeutics Inc. SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)Sierra Oncology (NASDAQ:SRRA)TapImmune Inc (NASDAQ:TPIV)Tarveda Therapeutics, Inc.Vascular Biogenics Ltd (NASDAQ:VBLT)Vidac Pharma

OphthamologyEyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)Graybug Vision, IncNemus Bioscience, Inc. (OTCQB:NMUS)Ocugen, Inc.pSivida Corp (NASDAQ:PSDV)

Orphan/Rare DiseaseAvidity Biosciences LLCCatalyst Biosciences (NASDAQ:CBIO) Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR)Muscular Dystrophy Association (MDA)Palladio Biosciences, Inc. Prometic Life Sciences Inc.

(Toronto:TSX: PLI, OTCQX : PFSCF)Summit Therapeutics plc (NASDAQ:SMMT)

Other22nd Century Group, Inc. (NYSE:XXII)Akebia Therapeutics, Inc. (NASDAQ:AKBA)Apricus Biosciences, Inc. (NASDAQ:APRI)Boston PharmaceuticalsCerecor Inc (NASDAQ:CERC) Oramed pharmaceuticals (NASDAQ:ORMP)

Platform for TherapeuticsBioTime (NYSE:BTX)Precision NanoSystems RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Regenerative MedicineRegenerative Medical Services Ltd.

Reproductive/Sexual HealthDaré Bioscience, Inc. (NASDAQ:DARE)S1 Biopharma, Inc.

RespiratoryInsmed Incorporated (NASDAQ:INSM)Lung Therapeutics, Inc. Novoclem Therapeutics Savara, Inc. (NASDAQ:SVRA)Spyryx Biosciences, Inc.

Tools/Drug Development Support TechScientist.com Soplix WuXi NextCODE


11.2 CAPITALA C Binder CorpAbbvie VenturesAceras Life SciencesAceras PartnersAcuris PartnersAdamas Healthcare FundAegis Capital CorpAFUNDAgent CapitalAgilent TechnologiesAisling Capital Aleph CapitalAlignment Ventures, LLCAllianceBernsteinAllied MindsAlly Bridge GroupAltaris Capital PartnersAltitude Life Science VenturesAmzak HealthAngelMDAnson FundsApple Tree Partners ARCH Venture PartnersArcher Avenue PartnersArcus VenturesAristar Capital Arjava Capital Group Arix BioscienceArowgrass Asahi Kasei AmericaAshford Capital ManagementAspire Capital Partners, LLCATEL VenturesATEM CapitalAthena Bio VenturesAtheneos CapitalAthyrium Capital ManagementAuGC BioFund LPAurora Asset ResearchB. Riley FBR, Inc.Bank of America Merrill LynchBawcapBentley Associates BergmorCapitalBigger Capital Fund, LPBioAdvanceBiondo Investment AdvisorsBiosense Global LLCBiosphere Capital VenturesBiotech Alliances InternationalBiotechnology Innovation OrganizationBlack Diamond Advisors, LLCBMO CapitalBohe Angel FundBojian CapitalBrace Pharma CapitalBridgebio Pharma LlcBrock Capital Brookline Capital MarketsC-Bridge CapitalCANA Partners Cato BioVenturesCEC Capital Cedrus InvestmentsChardanChardan Capital Markets, LLCChia Tai Tianqing Pharmaceutical GroupChurch Pension FundCL Investment GroupCrescent Capital Ventures LLCCross Current Research LLCCSC LeasingCS McKeeCTI Life SciencesDabar Investment AssociateesDec Family Ventures, LLCDeca Ventures, LLCDeerfield ManagementDiscover FundDiscover Fund Management LLLPDoubleRock LLCDouglas C. Lane & AssociatesDROIA nvDynamk CapitalEaston CapitalEfrat InvestmentsEGB VenturesEnsign Peak AdvisorsEnso VenturesEsousa Holdings LLCEvepine CapitalExcelyrate

Excelyrate CapitalFaridanFC Capital ManagementFederated Kaufmann Fund Ferghana PartnersFineman FinancialFirst Island CapitalFirst Seafront FundFirst Seafront Fund ManagementFlagship PioneeringFortress BiotechFirst Republic Investment ManagementGagnon Securities GCF Family OfficeGE VenturesGHS Investments, LLCGMP SecuritiesGMX Capital PartnersGolden SeedsGood Health CapitalGrant EngineGreensky CapitalGrey Sky Venture Partners Griffin SecuritiesGuggenheim PartnersGuggenheim SecuritiesH.C. Wainwright & Co.Hayfin Capital ManagementHCWCOHealth Passion FundHelix Management, IncHercules CapitalHorizons VenturesHorizons Ventures LtdHudson Bay Humanwell Healthcare Group Illumina VenturesInnoviva, Inc.inThought ResearchJ.P. MorganJanney Montgomery ScottJDRF T1D FundJefferies LLCJGB CapitalJina Ventures JMP Securities LLCJohnson & Johnson Innovation - JJDC Johnston Associates Inc.Kairos Ventures Kalka FundKarthala Capital Management (KCM)Katalyst SecuritiesKatalyst Securities LLCKatz Associates KESA Partners Inc.Kingdon Capital Knoll Capital Management Knott Partners, LPL2 CapitalL2 Capital, LLCLadenburg ThalmannLaidLaw and CompanyLazard Asset ManagementLexington Capital ManagementLifeScience Equity Partners, LLCLifeTech CapitalLincoln Park CapitalLittle Gem Life Science PartnersLivingston LLCLocust Walk CapitalLongitude CapitalLSWorks LLCLumira CapitalLYFE Capital Madison Square Capital LLCMarathon Asset ManagementMass Innovation LabsMaxim GroupMaytech Global InvestmentsMAZ Capital AdvisorsMedexMedex CapitalMedpro Investors LLCMentor Capital Partners LtdMeyers Investments Family Mid Atlantic Bio Angels (MABA)Militia Hill VenturesMizuho Corporate BankMizuho SecuritiesMorgan StanleyMorgens, Waterfall, Vintiadis & Co. Mossrock Capital Mossrock Capital, LLC

MP Healthcare Venture ManagementMSF Capital AdvisorsMurray Capital GroupMV Corp ServicesMVM PartnersMVP Capital PartnersNew Enterprise AssociatesNew Harbor Venture PartnersNew Jersey Division of InvestmentNew Science Global Healthcare FundNew Science VenturesNew York VenturesNexus Life Science PartnersNF Trinity CapitalNoble Life Science PartnersNovatio VenturesNSIP LLCNY VenturesNYICNYS Innovation VC FundOberland CapitalOmega FundsOpti Capital Management OrbiMed AdvisorsOrchard View Capital Advisors LpOtsuka America PharmaceuticalOtsuka Pharmaceutical Development

& Commercialization Oxford FinancePappas CapitalPappas VenturesPark Ave Capital Management

International Paulson InvestmentPeak One Opportunity Fund, LPPetrichor Healthcare Capital

ManagementPharmakon Advisors PHX Financial Piper Jaffray & Co.Pivotal BioVenture PartnersPortola Capital PartnersPrevail Partners, LLCPrinceton BioPharma Capital Partners Promethean Capital Group, LLCQILU PharmaceuticalQuestrionRBC Capital MarketsRelentless Pursuit PartnersRemiges VenturesRHK Capital LLCRho VenturesRobert W. Baird & Co., Inc.Rockport Venture FundRolin Capital Roosevelt InvestmentsRoth CapitalRoth Capital PartnersRTP Capital S&A InvestmentsSabby Management, LLCSagestone Capital / Elmwood CapitalSanten VenturesSatter ManagementSBP Management Schonfeld Strategic AdvisersSea Otter Global VenturesSeaport Global SecuritiesSecond Line Capital MgmtSerrado CapitalSeventureShattemac Capital ManagementShaw Strategic CapitalSilverArc CapitalSilver Arrow Partners

Sio CapitalSio Capital ManagementSlater Technology FundSmithOnStocksSnyder Capital ManagementSorrento TherapeuticsSpecial Situations FundsSPRIMSprim VenturesSquare 1 BankStadnyk and PartnersStanphyl Capital ManagementStifel FinancialSurveyor CapitalSutton Place ManagementSVBSymphonia PartnersSymphony Capital LLCSyzygy TherapeuticsTaiAn TechnologiesTalfinium Investments, Inc.Tanaka Capital ManagementTang Capital Management, LLCTAP AdvisorsThe Carlyle GroupThe Leukemia & Lymphoma SocietyTosoh USA, Inc.Tralucent Asset ManagementTryphon CapitalTurret Capital ManagementTwo Sigma VenturesUNUM CapitalValquest Capital ManagementVarana Capital, LLCVector CapitalvenBioVersant VenturesVirtus Inspire VenturesVista Capital AdvisorsVivo CapitalW Global Capital Ltd.Wallachbeth CapitalWBB Asset ManagementWBB SecuritiesWeigao GroupWellington Shields & Co. WestPark Capital Windrose Health InvestorsWolf Capital ManagementWolfswood PartnersYale UniversityXeraya Capital Life VentureZenith Capital

2018 PARTICIPATING INVESTORS

INVESTORREGISTRATION UP MORE THAN

35%OVER 2017.

100% of investors who attended BIO CEO in 2017 reported

that they found companies worth their consideration for investment.


BIO’s One-on-One Partnering™ system is the interactive platform that allows you to increase your productivity, discover new investment and licensing opportunities, and expand your business potential worldwide.

Using the system, companies are able to:

BIO ONE-ON-ONE PARTNERING MEETINGS

AUDIENCE DEMOGRAPHICS

76% of attendees are VP or C-Level

DirectorOther VPC-level

76%

9% 15% 62% 14%

Breakdown by Therapeutic Focus:

Job Profile:

Companies Profile:

58% of all companies attending are biopharma

Attendees: 1,400+Countries Represented: 28 BIO One-on-One Partnering Meetings: 2,600+Registered Investors: 650Company Presentations: 190Expert Speakers: 58

< $50M: 42%

$250M-500M: 4%

$100M-250M: 25%

$50M-100M: 16%

>$500M: 13%

Breakdown by Market Cap:

SCHEDULED MEETINGS

UP 21%SINCE 2015

88 Pre-schedule 30-minute private 1x1 meetings

88 Source potential collaborations and funding opportunities with an international audience

88 Communicate directly with prospective investors and C-level executives in biotech and pharma

88 Search company and investor profiles for potential business partnerships

76%

58%

Diagnostics: 7%

Oncology: 31%

Other: 26%

CNS/Neurological: 9%

Orphan/Rare Diseases: 6%

Gene/Cell Therapy: 5%

Infectious Diseases: 5%

Gastrointestinal: 4%

Metabolic Diseases: 4% Cardiovascular: 4%


SPONSORS

SUPPORTING BANK SPONSORS

DOUBLE HELIX SPONSORS

CONFERENCE SPONSORS

MEDIA PARTNERS

CO-HOSTS


ADVISORY COMMITTEE

Nouhad HusseiniVice President, Head of Business DevelopmentRegeneron Pharmaceuticals, Inc.

Susan Peschin, MHSPresident and Chief Executive OfficerAlliance for Aging Research

Sapna Srivastava, PhDChief Financial Officer and Chief Strategy OfficerAbide Therapeutics

John ChambersPresident and Head of Investment BankingH.C. Wainwright & Co.

Eric ChengManaging Director, Head of Healthcare Investment BankingROTH Capital Partners

Manon Cox, PhDTransition Task Force Leader (former President and CEO)Protein Sciences Corporation (acq. Sanofi Pasteur 2017)

Carol Gallagher, PharmDPartnerNew Enterprise Associates

Jonathan LeffPartner, Deerfield Management; ChairmanDeerfield Institute

Michael Margolis, RPhCo-Head of Healthcare Investment BankingOppenheimer & Co.

Timothy P. O’Connor, PhDExecutive Vice PresidentThe Rockefeller University

Jason Park, PhDPrincipalFlagship Pioneering

Linda S. Grais, MDPresident and Chief Executive OfficerOcera Therapeutics, Inc.

Dennis J. PurcellFounder and Senior AdvisorAisling Capital

Nassim Usman, PhDPresident and Chief Executive OfficerCatalyst Biosciences

Stephen M. RitochChairman and CEOBlaise Group International

Carlo Rizzuto, PhD,PartnerVersant Ventures

Matthew Roden, PhDHead of Strategic Corporate Development and Global BD AssessmentBristol-Myers Squibb

February 12-13, 2018 • New York Marriott Marquis


REGISTRATION AND HOUSING INFORMATION

BIO offers a number of ways to conference attendees to save money on their registration fees. Discounted rates apply to the following:

88 Companies bringing more than three employees.88 Academic, government and non-profit institutions.88 Service providers suppliers.

Qualified institutional and venture investors are eligible for complimentary registration.

CONTACT BIO REGISTRATIONEMAIL: [email protected]

TEL: +1.202.962.6655New York Marriott Marquis1535 Broadway, New York, NY 10036212.398.1900

Book your room today to also receive the discounted room rate. Reservation requests are based on availability, space is limited.

THIS YEAR’S EVENT

IS AT A NEW VENUE!

HOSTED BY:

conference - biotechnology innovation organization new approaches include allogenic car-t products,...

Documents